Get the Stockscreener App
7.59
0.13%
0.010
Nuvectis Pharma Inc stock is traded at $7.59, with a volume of 77,078.
It is up +0.13% in the last 24 hours and up +26.29% over the past month.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$7.58
Open:
$7.61
24h Volume:
77,078
Relative Volume:
0.78
Market Cap:
$194.42M
Revenue:
-
Net Income/Loss:
$-22.38M
P/E Ratio:
-5.383
EPS:
-1.41
Net Cash Flow:
$-15.54M
1W Performance:
+13.11%
1M Performance:
+26.29%
6M Performance:
-14.04%
1Y Performance:
+63.58%
1-Day Range:
$7.2639
$7.77
1-Week Range:
$6.47
$7.77
52-Week Range:
$4.44
$11.52
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Name
Nuvectis Pharma Inc
Sector
Industry
Phone
360-837-7232
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
7.59 | 194.16M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Maxim Group | Buy |
| Mar-17-25 | Initiated | Laidlaw | Buy |
| Jul-13-22 | Initiated | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Stock (NVCT) Latest News
Nuvectis Pharma Shares Gain Momentum on Analyst Backing and Clinical Progress - AD HOC NEWS
Published on: 2025-12-13 00:55:44 - earlytimes.in
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders - Yahoo Finance
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; individual investors who hold 44% profited and so did insiders - simplywall.st
Technical Reactions to NVCT Trends in Macro Strategies - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) Trading 9.8% HigherHere's What Happened - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Trading 9.8% Higher – Here’s What Happened - Defense World
Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Will Nuvectis Pharma Inc. stock attract more institutional investors2025 Trade Ideas & Technical Buy Zone Confirmations - Newser
Will Nuvectis Pharma Inc. stock split attract more investors2025 Price Momentum & Scalable Portfolio Growth Ideas - Newser
Published on: 2025-11-30 11:27:46 - BỘ NỘI VỤ
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC - marketscreener.com
Nuvectis Pharma to Host a Virtual Key Opinion Leader - GlobeNewswire
Nuvectis Pharma to Host Key Opinion Leader Meeting on NXP900 Phase 1b Program in Advanced Solid Tumors - Quiver Quantitative
Trading the Move, Not the Narrative: (NVCT) Edition - news.stocktradersdaily.com
How Nuvectis Pharma Inc. stock reacts to Fed rate cutsWeekly Profit Recap & Weekly Breakout Watchlists - newser.com
Nuvectis Pharma Inc. (NVCT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Nuvectis Pharma Inc. stock trendline breakdownPortfolio Risk Summary & Stock Market Timing Techniques - newser.com
How currency fluctuations impact Nuvectis Pharma Inc. stockEarnings Risk Summary & Weekly Watchlist for Consistent Profits - newser.com
What data driven models say about Nuvectis Pharma Inc.’s futureWeekly Gains Report & Reliable Volume Spike Trade Alerts - newser.com
Using RSI to spot recovery in Nuvectis Pharma Inc.Market Risk Report & Pattern Based Trade Signal System - newser.com
Predicting Nuvectis Pharma Inc. trend using moving averages2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
Top Analysts Predictions for Indobell Insulation Limited Stock Over 12 MonthsInsider Trading Activity & Free Unstoppable Trading Performance - earlytimes.in
What makes Nuvectis Pharma Inc. stock attractive to growth fundsMarket Volume Summary & Smart Investment Allocation Insights - newser.com
(NVCT) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Why Nuvectis Pharma Inc. stock remains undervaluedWeekly Market Outlook & Target Return Focused Stock Picks - newser.com
How Nuvectis Pharma Inc. stock performs in rate cut cycles2025 Market Sentiment & Stepwise Entry and Exit Trade Signals - newser.com
Director of Nuvectis Pharma Juan Sanchez Buys 20% More Shares - Yahoo Finance
Matthew Kaplan Acquires 11,000 Shares of Nuvectis Pharma (NASDAQ:NVCT) Stock - MarketBeat
Roth Capital Expects Lower Earnings for Nuvectis Pharma - Defense World
HC Wainwright Cuts Earnings Estimates for Nuvectis Pharma - Defense World
Nuvectis Pharma Executives Make Bold Moves with Major Stock Purchases! - TipRanks
Nuvectis Pharma director Sanchez buys $75k in NVCT stock By Investing.com - Investing.com Canada
Kaplan buys Nuvectis Pharma (NVCT) shares worth $64,240 By Investing.com - Investing.com South Africa
Insider Buying: Ron Bentsur Acquires Additional Shares of Nuvect - GuruFocus
Nuvectis Pharma director Sanchez buys $75k in NVCT stock - Investing.com
Kaplan buys Nuvectis Pharma (NVCT) shares worth $64,240 - Investing.com
Nuvectis Pharma chairman Bentsur buys $28,600 in shares By Investing.com - Investing.com Canada
Nuvectis Pharma Inc Stock (NVCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvectis Pharma Inc Stock (NVCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sanchez Juan | Director |
Nov 05 '25 |
Buy |
5.79 |
13,000 |
75,270 |
78,150 |
| Kaplan Matthew L. | Director |
Nov 05 '25 |
Buy |
5.84 |
11,000 |
64,240 |
124,760 |
| Mosseri Marlio Charles | 10% Owner |
Oct 27 '25 |
Buy |
6.28 |
72,836 |
457,410 |
3,136,576 |
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
| Mosseri Marlio Charles | 10% Owner |
Jun 20 '25 |
Buy |
7.99 |
5,603 |
44,768 |
2,981,806 |
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):